Tumor programmed death-1 ligand 1 (PD-L1) expression is also an important factor influencing therapeutic response to anti-PD-1 immunotherapy, with PD-L1-positive melanoma demonstrating a higher response rate to anti-PD-1 therapy compared to their PD-L1-negative counterpart [126]. Here, CD274 is linked to melanoma.